The Latest Cardiac and Vascular News
Company advances global neuro-intervention footprint with new CE-marked devices for vasospasm and stroke, and expanded U.S. indications for aspiration catheters. PLANO, Texas, Feb. 10, 2026 /PRNewswire/ — Vesalio, a global leader in vascular intervention, today announced CE Mark…
The FDA clearance of enVast redefines coronary thrombectomy treatment and further expands Vesalio’s commercial platform. PLANO, Texas, Dec. 11, 2025 /PRNewswire/ — Vesalio, a leader in thrombectomy solutions, today announced FDA 510(k) clearance and the upcoming U.S. commercial launch of…
Vesalio Introduces pVasc™ U.S. clinical study initiative to capture real-world data and optimize results for patients suffering from peripheral vascular disease PLANO, Texas, Oct. 25, 2024 /PRNewswire/ — Vesalio, a global thrombectomy company dedicated to advancing patient care across…
Nashville, TN (May 11, 2022) – Vesalio is excited to announce the completion of patient enrollment for the CLEAR1 FDA IDE study utilizing the NeVa™ thrombectomy platform. This is an important milestone for Vesalio to complete for entering the U.S. neurovascular market to treat patients suffering from acute ischemic stroke (AIS). AIS […]
Nashville, TN, October 31, 2017 –(PR.com)– Vesalio announces the CE Mark certification of its first product line, the proprietary NeVa™ neurothrombectomy platform for the treatment of strokes. Developed by a team of physicians that treat stroke, the NeVa mechanical thrombectomy technology was designed to improve “first pass” success, by effectively […]
